DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT03182296

UnknownPhase NA

Visualizing Beta Cells in Patients With a History of Gestational Diabetes

Asset

Exenatide

GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

24

estimated

Study population

Gestational diabetes, Healthy volunteers

Key I/E criteria

•BMI 17-30•Female

Primary endpoint

•Pancreatic uptake of 68Ga-NODAGA-exendin-4

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03182296
Org study IDNL56938.091.16

Timeline

Milestones

Study start2016-11-10actual
Study first posted2017-06-09actual
Last update posted2024-01-05actual
Primary completion2026-01-01estimated
Study completion2026-01-01estimated

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Gestational diabetesHealthy volunteers

Eligibility

Who can enroll

Minimum age18 Years
SexFemale
Healthy volunteersAccepted

Inclusion criteria

(women with a history of GDM):

•Pregnancy with diagnosis of GDM, within the last 5 years
•No other previous pregnancies
•Complete resolution of GDM after delivery
•No evidence of T2D at the time of inclusion
•BMI between 17 and 30
•Signed informed consent

Inclusion criteria (women without a history of GDM)

•Pregnancy without problems in glucose homeostasis, within the last 5 years
•No other previous pregnancies
•No evidence of T2D at time of inclusion
•Insulin secretion-sensitivity index-2 (ISSI-2) > 800 on oral glucose tolerance test
•BMI between 17 and 30
•Signed informed consent

Exclusion criteria

•Previous treatment (within 6 months) with synthetic exendin
•Breast feeding
•Current pregnancy
•Renal dysfunction
•Liver disease

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
1
Other (unclassified)
1

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint

C-peptide, HbA1c

Time frame:1 year

descriptive

Other (unclassified)

1 endpoint
Primary/protocol endpoint/low confidence

Pancreatic uptake of 68Ga-NODAGA-exendin-4

Time frame:1 year

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.